Enlivex Therapeutics Ltd. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ENLV Nasdaq 2836 www.enlivex.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Enlivex Therapeutics Ltd.

Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025 - Oct 28th, 2025 6:15 am
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Oct 3rd, 2025 7:00 am
D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program - Sep 29th, 2025 6:15 am
Enlivex Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Sep 19th, 2025 7:00 am
Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely? - Sep 14th, 2025 8:02 am
Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results - Sep 11th, 2025 6:00 am
Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis - Sep 9th, 2025 6:00 am
Enlivex advances lead cell therapy to Phase IIb in osteoarthritis - Aug 19th, 2025 5:53 am
Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis - Aug 18th, 2025 5:45 am
Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar - Aug 14th, 2025 6:30 am
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data - Jul 28th, 2025 6:30 am
Enlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Jun 13th, 2025 8:00 am
Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology - Jun 10th, 2025 6:30 am
Enlivex Selected to Present at Israeli BioMed 2025 Conference - May 20th, 2025 6:00 am
Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress - Apr 23rd, 2025 6:30 am
Enlivex enrols all patients in Phase II stage of knee osteoarthritis trial - Apr 22nd, 2025 4:17 am
Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis - Apr 21st, 2025 6:30 am
Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Invest In Growth? - Apr 7th, 2025 6:27 am
Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis - Apr 3rd, 2025 6:00 am
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis - Mar 17th, 2025 6:00 am